Mike Bastian

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.

Journal: The Journal of dermatological treatment

Published: June 01, 2026

A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".

A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".

Journal: Dermatology and therapy

Published: December 01, 2025

Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Journal: Paediatric drugs

Published: November 17, 2025

Identifying the Most Relevant Eczema Area and Severity Index Thresholds from the Patient Perspective in Atopic Dermatitis Treatment.

Identifying the Most Relevant Eczema Area and Severity Index Thresholds from the Patient Perspective in Atopic Dermatitis Treatment.

Journal: American journal of clinical dermatology

Published: October 29, 2025

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.

Journal: Advances in therapy

Published: September 04, 2025

Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.

Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.

Journal: Dermatology and therapy

Published: June 03, 2025

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.

Journal: Dermatology and therapy

Published: April 15, 2025

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials.

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials.

Journal: Advances in therapy

Published: November 14, 2024

Detecting diversifying selection for a trait from within and between-species genotypes and phenotypes.

Detecting diversifying selection for a trait from within and between-species genotypes and phenotypes.

Journal: Journal of evolutionary biology

Published: June 14, 2024

Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166.

Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166.

Journal: Journal of medical economics

Published: June 06, 2024

Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Journal: Advances in therapy

Published: May 02, 2024

Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.

Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.

Journal: Dermatology and therapy

Published: December 11, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026